nodes	percent_of_prediction	percent_of_DWPC	metapath
Finasteride—Infertility male—Thiotepa—urinary bladder cancer	0.068	0.142	CcSEcCtD
Finasteride—AKR1D1—female reproductive system—urinary bladder cancer	0.033	0.241	CbGeAlD
Finasteride—SRD5A1—prostate gland—urinary bladder cancer	0.0323	0.236	CbGeAlD
Finasteride—SRD5A1—renal system—urinary bladder cancer	0.022	0.161	CbGeAlD
Finasteride—Breast cancer—Gemcitabine—urinary bladder cancer	0.0181	0.0378	CcSEcCtD
Finasteride—SRD5A1—female reproductive system—urinary bladder cancer	0.0176	0.129	CbGeAlD
Finasteride—CYP3A4—urine—urinary bladder cancer	0.0129	0.0941	CbGeAlD
Finasteride—Oedema peripheral—Valrubicin—urinary bladder cancer	0.0112	0.0234	CcSEcCtD
Finasteride—Neoplasm malignant—Thiotepa—urinary bladder cancer	0.00917	0.0192	CcSEcCtD
Finasteride—Neoplasm malignant—Gemcitabine—urinary bladder cancer	0.00772	0.0161	CcSEcCtD
Finasteride—Tenderness—Gemcitabine—urinary bladder cancer	0.00755	0.0158	CcSEcCtD
Finasteride—Tenderness—Fluorouracil—urinary bladder cancer	0.00743	0.0155	CcSEcCtD
Finasteride—Infection—Carboplatin—urinary bladder cancer	0.00742	0.0155	CcSEcCtD
Finasteride—Prostatic disorder—Epirubicin—urinary bladder cancer	0.00742	0.0155	CcSEcCtD
Finasteride—Tenderness—Cisplatin—urinary bladder cancer	0.00704	0.0147	CcSEcCtD
Finasteride—Prostatic disorder—Doxorubicin—urinary bladder cancer	0.00687	0.0144	CcSEcCtD
Finasteride—Pain—Carboplatin—urinary bladder cancer	0.00639	0.0134	CcSEcCtD
Finasteride—CYP3A5—prostate gland—urinary bladder cancer	0.00616	0.045	CbGeAlD
Finasteride—Asthenia—Valrubicin—urinary bladder cancer	0.00579	0.0121	CcSEcCtD
Finasteride—Pruritus—Valrubicin—urinary bladder cancer	0.00571	0.0119	CcSEcCtD
Finasteride—Dizziness—Valrubicin—urinary bladder cancer	0.00533	0.0112	CcSEcCtD
Finasteride—Swelling—Fluorouracil—urinary bladder cancer	0.00533	0.0111	CcSEcCtD
Finasteride—Rash—Valrubicin—urinary bladder cancer	0.00509	0.0106	CcSEcCtD
Finasteride—Dermatitis—Valrubicin—urinary bladder cancer	0.00508	0.0106	CcSEcCtD
Finasteride—Headache—Valrubicin—urinary bladder cancer	0.00505	0.0106	CcSEcCtD
Finasteride—Dyspnoea—Mitomycin—urinary bladder cancer	0.00496	0.0104	CcSEcCtD
Finasteride—Somnolence—Mitomycin—urinary bladder cancer	0.00494	0.0103	CcSEcCtD
Finasteride—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00476	0.0124	CbGpPWpGaD
Finasteride—Pain—Mitomycin—urinary bladder cancer	0.00475	0.00994	CcSEcCtD
Finasteride—Swelling—Etoposide—urinary bladder cancer	0.00463	0.00968	CcSEcCtD
Finasteride—CYP3A7—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00446	0.0116	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.0043	0.0112	CbGpPWpGaD
Finasteride—CYP3A5—renal system—urinary bladder cancer	0.0042	0.0307	CbGeAlD
Finasteride—Influenza—Gemcitabine—urinary bladder cancer	0.00413	0.00864	CcSEcCtD
Finasteride—Orthostatic hypotension—Cisplatin—urinary bladder cancer	0.00407	0.00851	CcSEcCtD
Finasteride—Breast disorder—Cisplatin—urinary bladder cancer	0.00403	0.00842	CcSEcCtD
Finasteride—Asthenia—Mitomycin—urinary bladder cancer	0.00399	0.00834	CcSEcCtD
Finasteride—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00398	0.0103	CbGpPWpGaD
Finasteride—AKR1D1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00395	0.0103	CbGpPWpGaD
Finasteride—CYP3A5—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00393	0.0102	CbGpPWpGaD
Finasteride—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00386	0.01	CbGpPWpGaD
Finasteride—Neoplasm malignant—Epirubicin—urinary bladder cancer	0.00369	0.00772	CcSEcCtD
Finasteride—Dizziness—Mitomycin—urinary bladder cancer	0.00368	0.00768	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00363	0.00944	CbGpPWpGaD
Finasteride—Immune system disorder—Thiotepa—urinary bladder cancer	0.00355	0.00743	CcSEcCtD
Finasteride—Rash—Mitomycin—urinary bladder cancer	0.0035	0.00733	CcSEcCtD
Finasteride—Dermatitis—Mitomycin—urinary bladder cancer	0.0035	0.00732	CcSEcCtD
Finasteride—Headache—Mitomycin—urinary bladder cancer	0.00348	0.00728	CcSEcCtD
Finasteride—Mental disorder—Thiotepa—urinary bladder cancer	0.00345	0.00721	CcSEcCtD
Finasteride—Neoplasm malignant—Doxorubicin—urinary bladder cancer	0.00342	0.00715	CcSEcCtD
Finasteride—Sinusitis—Fluorouracil—urinary bladder cancer	0.0034	0.00711	CcSEcCtD
Finasteride—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00339	0.00881	CbGpPWpGaD
Finasteride—Rhinitis—Gemcitabine—urinary bladder cancer	0.00332	0.00694	CcSEcCtD
Finasteride—Pharyngitis—Gemcitabine—urinary bladder cancer	0.00328	0.00687	CcSEcCtD
Finasteride—Rhinitis—Fluorouracil—urinary bladder cancer	0.00326	0.00682	CcSEcCtD
Finasteride—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.00326	0.00682	CcSEcCtD
Finasteride—Pharyngitis—Fluorouracil—urinary bladder cancer	0.00323	0.00675	CcSEcCtD
Finasteride—CYP3A5—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00323	0.00838	CbGpPWpGaD
Finasteride—CYP3A5—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00321	0.00835	CbGpPWpGaD
Finasteride—CYP3A4—renal system—urinary bladder cancer	0.00315	0.023	CbGeAlD
Finasteride—Neoplasm—Methotrexate—urinary bladder cancer	0.00305	0.00637	CcSEcCtD
Finasteride—CYP3A5—vagina—urinary bladder cancer	0.00304	0.0222	CbGeAlD
Finasteride—CYP3A7—Biological oxidations—GSTZ1—urinary bladder cancer	0.00304	0.00789	CbGpPWpGaD
Finasteride—Gynaecomastia—Methotrexate—urinary bladder cancer	0.00302	0.0063	CcSEcCtD
Finasteride—CYP3A7—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00299	0.00778	CbGpPWpGaD
Finasteride—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00299	0.00625	CcSEcCtD
Finasteride—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00291	0.00757	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—GSTO2—urinary bladder cancer	0.00288	0.00748	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—NAT1—urinary bladder cancer	0.00288	0.00748	CbGpPWpGaD
Finasteride—Neoplasm—Epirubicin—urinary bladder cancer	0.00285	0.00596	CcSEcCtD
Finasteride—CYP3A7—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00284	0.00738	CbGpPWpGaD
Finasteride—Immune system disorder—Cisplatin—urinary bladder cancer	0.00279	0.00582	CcSEcCtD
Finasteride—Infection—Thiotepa—urinary bladder cancer	0.00278	0.0058	CcSEcCtD
Finasteride—SRD5A1—Metabolism—GSTZ1—urinary bladder cancer	0.00275	0.00716	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—GSTZ1—urinary bladder cancer	0.00275	0.00716	CbGpPWpGaD
Finasteride—Neoplasm—Doxorubicin—urinary bladder cancer	0.00264	0.00552	CcSEcCtD
Finasteride—CYP3A7—Biological oxidations—UGT2B7—urinary bladder cancer	0.00263	0.00684	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—GSTO2—urinary bladder cancer	0.00261	0.00678	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—GSTO2—urinary bladder cancer	0.00261	0.00678	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—NAT1—urinary bladder cancer	0.00261	0.00678	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—NAT1—urinary bladder cancer	0.00261	0.00678	CbGpPWpGaD
Finasteride—CYP3A7—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.0026	0.00675	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.00257	0.00667	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.00257	0.00667	CbGpPWpGaD
Finasteride—Immune system disorder—Etoposide—urinary bladder cancer	0.00255	0.00534	CcSEcCtD
Finasteride—CYP3A4—female reproductive system—urinary bladder cancer	0.00253	0.0184	CbGeAlD
Finasteride—Somnolence—Thiotepa—urinary bladder cancer	0.00248	0.00519	CcSEcCtD
Finasteride—AKR1D1—Metabolism—GSTZ1—urinary bladder cancer	0.00245	0.00638	CbGpPWpGaD
Finasteride—Pain—Thiotepa—urinary bladder cancer	0.00239	0.005	CcSEcCtD
Finasteride—SRD5A2—Metabolism—UGT2B7—urinary bladder cancer	0.00239	0.00621	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—UGT2B7—urinary bladder cancer	0.00239	0.00621	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—CYP4B1—urinary bladder cancer	0.00237	0.00616	CbGpPWpGaD
Finasteride—CYP3A7—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00234	0.00608	CbGpPWpGaD
Finasteride—Infection—Gemcitabine—urinary bladder cancer	0.00234	0.00488	CcSEcCtD
Finasteride—AKR1D1—Metabolism—GSTO2—urinary bladder cancer	0.00233	0.00605	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—NAT1—urinary bladder cancer	0.00233	0.00605	CbGpPWpGaD
Finasteride—Infection—Fluorouracil—urinary bladder cancer	0.0023	0.0048	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.00229	0.00595	CbGpPWpGaD
Finasteride—Urticaria—Thiotepa—urinary bladder cancer	0.00222	0.00464	CcSEcCtD
Finasteride—Breast disorder—Methotrexate—urinary bladder cancer	0.00221	0.00462	CcSEcCtD
Finasteride—Hypotension—Gemcitabine—urinary bladder cancer	0.0022	0.00459	CcSEcCtD
Finasteride—CYP3A5—Biological oxidations—GSTZ1—urinary bladder cancer	0.00219	0.0057	CbGpPWpGaD
Finasteride—Infection—Cisplatin—urinary bladder cancer	0.00218	0.00455	CcSEcCtD
Finasteride—CYP3A5—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00216	0.00563	CbGpPWpGaD
Finasteride—Hypotension—Fluorouracil—urinary bladder cancer	0.00216	0.00452	CcSEcCtD
Finasteride—SRD5A1—Metabolism—CYP4B1—urinary bladder cancer	0.00215	0.00559	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—CYP4B1—urinary bladder cancer	0.00215	0.00559	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—UGT2B7—urinary bladder cancer	0.00213	0.00553	CbGpPWpGaD
Finasteride—Dyspnoea—Gemcitabine—urinary bladder cancer	0.0021	0.00438	CcSEcCtD
Finasteride—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00209	0.00437	CcSEcCtD
Finasteride—Somnolence—Gemcitabine—urinary bladder cancer	0.00209	0.00437	CcSEcCtD
Finasteride—CYP3A5—Biological oxidations—GSTO2—urinary bladder cancer	0.00208	0.00541	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—NAT1—urinary bladder cancer	0.00208	0.00541	CbGpPWpGaD
Finasteride—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.00208	0.0054	CbGpPWpGaD
Finasteride—Breast disorder—Epirubicin—urinary bladder cancer	0.00207	0.00433	CcSEcCtD
Finasteride—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00206	0.00431	CcSEcCtD
Finasteride—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00206	0.0043	CcSEcCtD
Finasteride—Somnolence—Fluorouracil—urinary bladder cancer	0.00206	0.0043	CcSEcCtD
Finasteride—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00205	0.00533	CbGpPWpGaD
Finasteride—Hypotension—Cisplatin—urinary bladder cancer	0.00205	0.00428	CcSEcCtD
Finasteride—SRD5A1—Metabolism—SLC19A1—urinary bladder cancer	0.00203	0.00528	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—SLC19A1—urinary bladder cancer	0.00203	0.00528	CbGpPWpGaD
Finasteride—Pain—Gemcitabine—urinary bladder cancer	0.00201	0.0042	CcSEcCtD
Finasteride—Asthenia—Thiotepa—urinary bladder cancer	0.00201	0.00419	CcSEcCtD
Finasteride—Infection—Etoposide—urinary bladder cancer	0.00199	0.00417	CcSEcCtD
Finasteride—Influenza—Epirubicin—urinary bladder cancer	0.00198	0.00414	CcSEcCtD
Finasteride—SRD5A2—Metabolism—PRSS3—urinary bladder cancer	0.00198	0.00514	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PRSS3—urinary bladder cancer	0.00198	0.00514	CbGpPWpGaD
Finasteride—Pruritus—Thiotepa—urinary bladder cancer	0.00198	0.00413	CcSEcCtD
Finasteride—Pain—Fluorouracil—urinary bladder cancer	0.00198	0.00413	CcSEcCtD
Finasteride—Dyspnoea—Cisplatin—urinary bladder cancer	0.00195	0.00408	CcSEcCtD
Finasteride—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00195	0.00407	CcSEcCtD
Finasteride—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00194	0.00405	CcSEcCtD
Finasteride—AKR1D1—Metabolism—CYP4B1—urinary bladder cancer	0.00192	0.00498	CbGpPWpGaD
Finasteride—Breast disorder—Doxorubicin—urinary bladder cancer	0.00191	0.004	CcSEcCtD
Finasteride—Bronchitis—Epirubicin—urinary bladder cancer	0.0019	0.00398	CcSEcCtD
Finasteride—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.0019	0.00495	CbGpPWpGaD
Finasteride—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00188	0.00488	CbGpPWpGaD
Finasteride—Hypotension—Etoposide—urinary bladder cancer	0.00188	0.00392	CcSEcCtD
Finasteride—Pain—Cisplatin—urinary bladder cancer	0.00187	0.00392	CcSEcCtD
Finasteride—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00185	0.00481	CbGpPWpGaD
Finasteride—Dizziness—Thiotepa—urinary bladder cancer	0.00185	0.00386	CcSEcCtD
Finasteride—Urticaria—Fluorouracil—urinary bladder cancer	0.00184	0.00384	CcSEcCtD
Finasteride—Influenza—Doxorubicin—urinary bladder cancer	0.00183	0.00383	CcSEcCtD
Finasteride—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00183	0.00474	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—SLC19A1—urinary bladder cancer	0.00181	0.0047	CbGpPWpGaD
Finasteride—Dyspnoea—Etoposide—urinary bladder cancer	0.00179	0.00374	CcSEcCtD
Finasteride—Somnolence—Etoposide—urinary bladder cancer	0.00178	0.00373	CcSEcCtD
Finasteride—AKR1D1—Metabolism—PRSS3—urinary bladder cancer	0.00176	0.00458	CbGpPWpGaD
Finasteride—Rash—Thiotepa—urinary bladder cancer	0.00176	0.00368	CcSEcCtD
Finasteride—Bronchitis—Doxorubicin—urinary bladder cancer	0.00176	0.00368	CcSEcCtD
Finasteride—Dermatitis—Thiotepa—urinary bladder cancer	0.00176	0.00368	CcSEcCtD
Finasteride—Headache—Thiotepa—urinary bladder cancer	0.00175	0.00366	CcSEcCtD
Finasteride—Pain—Etoposide—urinary bladder cancer	0.00172	0.00359	CcSEcCtD
Finasteride—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.00171	0.00445	CbGpPWpGaD
Finasteride—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.0017	0.00356	CcSEcCtD
Finasteride—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00169	0.00439	CbGpPWpGaD
Finasteride—Asthenia—Gemcitabine—urinary bladder cancer	0.00169	0.00353	CcSEcCtD
Finasteride—Pharyngitis—Methotrexate—urinary bladder cancer	0.00168	0.00351	CcSEcCtD
Finasteride—Pruritus—Gemcitabine—urinary bladder cancer	0.00166	0.00348	CcSEcCtD
Finasteride—Sinusitis—Epirubicin—urinary bladder cancer	0.00166	0.00346	CcSEcCtD
Finasteride—Pruritus—Fluorouracil—urinary bladder cancer	0.00164	0.00342	CcSEcCtD
Finasteride—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00161	0.00338	CcSEcCtD
Finasteride—Urticaria—Etoposide—urinary bladder cancer	0.00159	0.00333	CcSEcCtD
Finasteride—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00159	0.00414	CbGpPWpGaD
Finasteride—Rhinitis—Epirubicin—urinary bladder cancer	0.00159	0.00332	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.00159	0.00412	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.00159	0.00412	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—TYMP—urinary bladder cancer	0.00158	0.00411	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—TYMP—urinary bladder cancer	0.00158	0.00411	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—NAT2—urinary bladder cancer	0.00158	0.0041	CbGpPWpGaD
Finasteride—Asthenia—Cisplatin—urinary bladder cancer	0.00157	0.00329	CcSEcCtD
Finasteride—Pharyngitis—Epirubicin—urinary bladder cancer	0.00157	0.00329	CcSEcCtD
Finasteride—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00156	0.00326	CcSEcCtD
Finasteride—CYP3A7—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00156	0.00404	CbGpPWpGaD
Finasteride—Sinusitis—Doxorubicin—urinary bladder cancer	0.00153	0.0032	CcSEcCtD
Finasteride—Immune system disorder—Methotrexate—urinary bladder cancer	0.00153	0.0032	CcSEcCtD
Finasteride—Dizziness—Fluorouracil—urinary bladder cancer	0.00153	0.0032	CcSEcCtD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.00152	0.00395	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.00152	0.00395	CbGpPWpGaD
Finasteride—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.0015	0.0039	CbGpPWpGaD
Finasteride—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00149	0.00388	CbGpPWpGaD
Finasteride—Mental disorder—Methotrexate—urinary bladder cancer	0.00148	0.0031	CcSEcCtD
Finasteride—Rash—Gemcitabine—urinary bladder cancer	0.00148	0.0031	CcSEcCtD
Finasteride—Dermatitis—Gemcitabine—urinary bladder cancer	0.00148	0.0031	CcSEcCtD
Finasteride—Hypersensitivity—Etoposide—urinary bladder cancer	0.00148	0.00309	CcSEcCtD
Finasteride—Headache—Gemcitabine—urinary bladder cancer	0.00147	0.00308	CcSEcCtD
Finasteride—Rhinitis—Doxorubicin—urinary bladder cancer	0.00147	0.00307	CcSEcCtD
Finasteride—Rash—Fluorouracil—urinary bladder cancer	0.00146	0.00305	CcSEcCtD
Finasteride—Dermatitis—Fluorouracil—urinary bladder cancer	0.00146	0.00304	CcSEcCtD
Finasteride—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00145	0.00304	CcSEcCtD
Finasteride—Headache—Fluorouracil—urinary bladder cancer	0.00145	0.00303	CcSEcCtD
Finasteride—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00144	0.00302	CcSEcCtD
Finasteride—Asthenia—Etoposide—urinary bladder cancer	0.00144	0.00301	CcSEcCtD
Finasteride—Immune system disorder—Epirubicin—urinary bladder cancer	0.00143	0.00299	CcSEcCtD
Finasteride—SRD5A2—Metabolism—NAT2—urinary bladder cancer	0.00143	0.00372	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—NAT2—urinary bladder cancer	0.00143	0.00372	CbGpPWpGaD
Finasteride—Pruritus—Etoposide—urinary bladder cancer	0.00142	0.00297	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.00141	0.00367	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—TYMP—urinary bladder cancer	0.00141	0.00366	CbGpPWpGaD
Finasteride—Mental disorder—Epirubicin—urinary bladder cancer	0.00139	0.0029	CcSEcCtD
Finasteride—Rash—Cisplatin—urinary bladder cancer	0.00138	0.00289	CcSEcCtD
Finasteride—Dermatitis—Cisplatin—urinary bladder cancer	0.00138	0.00289	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.00135	0.00352	CbGpPWpGaD
Finasteride—Dizziness—Etoposide—urinary bladder cancer	0.00133	0.00278	CcSEcCtD
Finasteride—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00132	0.00277	CcSEcCtD
Finasteride—Mental disorder—Doxorubicin—urinary bladder cancer	0.00128	0.00268	CcSEcCtD
Finasteride—AKR1D1—Metabolism—NAT2—urinary bladder cancer	0.00127	0.00331	CbGpPWpGaD
Finasteride—Rash—Etoposide—urinary bladder cancer	0.00127	0.00265	CcSEcCtD
Finasteride—Dermatitis—Etoposide—urinary bladder cancer	0.00126	0.00264	CcSEcCtD
Finasteride—CYP3A7—Biological oxidations—HPGDS—urinary bladder cancer	0.00126	0.00328	CbGpPWpGaD
Finasteride—Headache—Etoposide—urinary bladder cancer	0.00126	0.00263	CcSEcCtD
Finasteride—SRD5A1—Metabolism—RRM2—urinary bladder cancer	0.00123	0.00321	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—RRM2—urinary bladder cancer	0.00123	0.00321	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—GSTT1—urinary bladder cancer	0.00122	0.00318	CbGpPWpGaD
Finasteride—Infection—Methotrexate—urinary bladder cancer	0.00119	0.0025	CcSEcCtD
Finasteride—SRD5A2—Metabolism—HPGDS—urinary bladder cancer	0.00114	0.00297	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—HPGDS—urinary bladder cancer	0.00114	0.00297	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—ENO2—urinary bladder cancer	0.00114	0.00297	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—ENO2—urinary bladder cancer	0.00114	0.00297	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.00114	0.00296	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.00114	0.00295	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.00114	0.00295	CbGpPWpGaD
Finasteride—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00112	0.00292	CbGpPWpGaD
Finasteride—Hypotension—Methotrexate—urinary bladder cancer	0.00112	0.00235	CcSEcCtD
Finasteride—Infection—Epirubicin—urinary bladder cancer	0.00112	0.00234	CcSEcCtD
Finasteride—SRD5A1—Metabolism—GSTT1—urinary bladder cancer	0.00111	0.00288	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—GSTT1—urinary bladder cancer	0.00111	0.00288	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—RRM2—urinary bladder cancer	0.0011	0.00286	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.00109	0.00284	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.00109	0.00284	CbGpPWpGaD
Finasteride—Dyspnoea—Methotrexate—urinary bladder cancer	0.00107	0.00224	CcSEcCtD
Finasteride—Somnolence—Methotrexate—urinary bladder cancer	0.00107	0.00223	CcSEcCtD
Finasteride—Hypotension—Epirubicin—urinary bladder cancer	0.00105	0.0022	CcSEcCtD
Finasteride—Infection—Doxorubicin—urinary bladder cancer	0.00103	0.00216	CcSEcCtD
Finasteride—Pain—Methotrexate—urinary bladder cancer	0.00103	0.00215	CcSEcCtD
Finasteride—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.00102	0.00265	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—ENO2—urinary bladder cancer	0.00102	0.00265	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—HPGDS—urinary bladder cancer	0.00102	0.00265	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.00101	0.00263	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00101	0.00262	CbGpPWpGaD
Finasteride—Dyspnoea—Epirubicin—urinary bladder cancer	0.001	0.0021	CcSEcCtD
Finasteride—Somnolence—Epirubicin—urinary bladder cancer	0.001	0.00209	CcSEcCtD
Finasteride—AKR1D1—Metabolism—GSTT1—urinary bladder cancer	0.000988	0.00257	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000973	0.00253	CbGpPWpGaD
Finasteride—Hypotension—Doxorubicin—urinary bladder cancer	0.000973	0.00203	CcSEcCtD
Finasteride—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000967	0.00251	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000967	0.00251	CbGpPWpGaD
Finasteride—Pain—Epirubicin—urinary bladder cancer	0.000962	0.00201	CcSEcCtD
Finasteride—Urticaria—Methotrexate—urinary bladder cancer	0.000955	0.002	CcSEcCtD
Finasteride—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000954	0.00248	CbGpPWpGaD
Finasteride—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000928	0.00194	CcSEcCtD
Finasteride—Somnolence—Doxorubicin—urinary bladder cancer	0.000926	0.00194	CcSEcCtD
Finasteride—SRD5A2—Metabolism—NQO1—urinary bladder cancer	0.000921	0.0024	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—NQO1—urinary bladder cancer	0.000921	0.0024	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	0.000911	0.00237	CbGpPWpGaD
Finasteride—Urticaria—Epirubicin—urinary bladder cancer	0.000894	0.00187	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000894	0.00232	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000894	0.00232	CbGpPWpGaD
Finasteride—Pain—Doxorubicin—urinary bladder cancer	0.00089	0.00186	CcSEcCtD
Finasteride—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000886	0.00185	CcSEcCtD
Finasteride—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000885	0.0023	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	0.000884	0.0023	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000872	0.00227	CbGpPWpGaD
Finasteride—Asthenia—Methotrexate—urinary bladder cancer	0.000863	0.0018	CcSEcCtD
Finasteride—Pruritus—Methotrexate—urinary bladder cancer	0.000851	0.00178	CcSEcCtD
Finasteride—CYP3A7—Biological oxidations—GSTP1—urinary bladder cancer	0.000847	0.0022	CbGpPWpGaD
Finasteride—CYP3A7—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000836	0.00217	CbGpPWpGaD
Finasteride—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000829	0.00173	CcSEcCtD
Finasteride—Urticaria—Doxorubicin—urinary bladder cancer	0.000827	0.00173	CcSEcCtD
Finasteride—AKR1D1—Metabolism—NQO1—urinary bladder cancer	0.000821	0.00213	CbGpPWpGaD
Finasteride—Asthenia—Epirubicin—urinary bladder cancer	0.000807	0.00169	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000797	0.00207	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000796	0.00207	CbGpPWpGaD
Finasteride—Pruritus—Epirubicin—urinary bladder cancer	0.000796	0.00166	CcSEcCtD
Finasteride—Dizziness—Methotrexate—urinary bladder cancer	0.000795	0.00166	CcSEcCtD
Finasteride—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000785	0.00204	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.00078	0.00203	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.00078	0.00203	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—GSTM1—urinary bladder cancer	0.000779	0.00202	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—GSTP1—urinary bladder cancer	0.000769	0.002	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—GSTP1—urinary bladder cancer	0.000769	0.002	CbGpPWpGaD
Finasteride—CYP3A7—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000768	0.002	CbGpPWpGaD
Finasteride—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000767	0.0016	CcSEcCtD
Finasteride—Rash—Methotrexate—urinary bladder cancer	0.000758	0.00159	CcSEcCtD
Finasteride—Dermatitis—Methotrexate—urinary bladder cancer	0.000758	0.00158	CcSEcCtD
Finasteride—Headache—Methotrexate—urinary bladder cancer	0.000753	0.00157	CcSEcCtD
Finasteride—Asthenia—Doxorubicin—urinary bladder cancer	0.000747	0.00156	CcSEcCtD
Finasteride—Dizziness—Epirubicin—urinary bladder cancer	0.000744	0.00156	CcSEcCtD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000744	0.00193	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000744	0.00193	CbGpPWpGaD
Finasteride—Pruritus—Doxorubicin—urinary bladder cancer	0.000737	0.00154	CcSEcCtD
Finasteride—SRD5A2—Metabolism—TYMS—urinary bladder cancer	0.000714	0.00186	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—TYMS—urinary bladder cancer	0.000714	0.00186	CbGpPWpGaD
Finasteride—Rash—Epirubicin—urinary bladder cancer	0.00071	0.00148	CcSEcCtD
Finasteride—Dermatitis—Epirubicin—urinary bladder cancer	0.000709	0.00148	CcSEcCtD
Finasteride—SRD5A1—Metabolism—NCOR1—urinary bladder cancer	0.000706	0.00184	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—GSTM1—urinary bladder cancer	0.000706	0.00184	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—NCOR1—urinary bladder cancer	0.000706	0.00184	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—GSTM1—urinary bladder cancer	0.000706	0.00184	CbGpPWpGaD
Finasteride—Headache—Epirubicin—urinary bladder cancer	0.000705	0.00147	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000695	0.00181	CbGpPWpGaD
Finasteride—Dizziness—Doxorubicin—urinary bladder cancer	0.000689	0.00144	CcSEcCtD
Finasteride—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000686	0.00178	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—GSTP1—urinary bladder cancer	0.000685	0.00178	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—GPX1—urinary bladder cancer	0.000676	0.00176	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—GPX1—urinary bladder cancer	0.000676	0.00176	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—ERCC2—urinary bladder cancer	0.000664	0.00173	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—ERCC2—urinary bladder cancer	0.000664	0.00173	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000663	0.00172	CbGpPWpGaD
Finasteride—Rash—Doxorubicin—urinary bladder cancer	0.000657	0.00137	CcSEcCtD
Finasteride—Dermatitis—Doxorubicin—urinary bladder cancer	0.000656	0.00137	CcSEcCtD
Finasteride—Headache—Doxorubicin—urinary bladder cancer	0.000652	0.00136	CcSEcCtD
Finasteride—AKR1D1—Metabolism—TYMS—urinary bladder cancer	0.000637	0.00166	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—NCOR1—urinary bladder cancer	0.000629	0.00164	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—GSTM1—urinary bladder cancer	0.000629	0.00164	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—MTHFR—urinary bladder cancer	0.000624	0.00162	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—MTHFR—urinary bladder cancer	0.000624	0.00162	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000613	0.00159	CbGpPWpGaD
Finasteride—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000604	0.00157	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—GPX1—urinary bladder cancer	0.000603	0.00157	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—ERCC2—urinary bladder cancer	0.000592	0.00154	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000563	0.00146	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—MTHFR—urinary bladder cancer	0.000556	0.00145	CbGpPWpGaD
Finasteride—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000555	0.00144	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.00053	0.00138	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000523	0.00136	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	0.000519	0.00135	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PPARG—urinary bladder cancer	0.000506	0.00132	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—PPARG—urinary bladder cancer	0.000506	0.00132	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—NAT1—urinary bladder cancer	0.000492	0.00128	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	0.000492	0.00128	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—CREBBP—urinary bladder cancer	0.000486	0.00126	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—CREBBP—urinary bladder cancer	0.000486	0.00126	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—PPARG—urinary bladder cancer	0.000451	0.00117	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	0.00045	0.00117	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—CREBBP—urinary bladder cancer	0.000433	0.00113	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000424	0.0011	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000411	0.00107	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	0.000405	0.00105	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PTGS2—urinary bladder cancer	0.000398	0.00104	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—PTGS2—urinary bladder cancer	0.000398	0.00104	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	0.000383	0.000995	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.000375	0.000976	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	0.000373	0.00097	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.000356	0.000925	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.000356	0.000925	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—PTGS2—urinary bladder cancer	0.000355	0.000923	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—PTEN—urinary bladder cancer	0.000347	0.000903	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PTEN—urinary bladder cancer	0.000347	0.000903	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—EP300—urinary bladder cancer	0.000331	0.000861	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—EP300—urinary bladder cancer	0.000331	0.000861	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	0.000325	0.000846	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—PTEN—urinary bladder cancer	0.000309	0.000805	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—TYMP—urinary bladder cancer	0.000298	0.000775	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—EP300—urinary bladder cancer	0.000295	0.000767	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	0.000293	0.000762	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000285	0.00074	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000281	0.00073	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	0.000277	0.000719	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—NAT2—urinary bladder cancer	0.00027	0.000701	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	0.00027	0.000701	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000262	0.00068	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000258	0.000671	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—RRM2—urinary bladder cancer	0.000233	0.000605	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—ENO2—urinary bladder cancer	0.000216	0.00056	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	0.000216	0.00056	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—TYMP—urinary bladder cancer	0.000216	0.00056	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	0.000209	0.000544	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—NAT2—urinary bladder cancer	0.000195	0.000507	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	0.000174	0.000454	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—NQO1—urinary bladder cancer	0.000174	0.000452	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—RRM2—urinary bladder cancer	0.000168	0.000437	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	0.000165	0.00043	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—NAT1—urinary bladder cancer	0.000165	0.00043	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—ENO2—urinary bladder cancer	0.000156	0.000405	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	0.000156	0.000405	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	0.000151	0.000393	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	0.000151	0.000393	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	0.000145	0.000377	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	0.000136	0.000354	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—TYMS—urinary bladder cancer	0.000135	0.00035	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	0.000133	0.000346	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	0.000133	0.000346	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	0.000129	0.000334	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—GPX1—urinary bladder cancer	0.000128	0.000332	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—NQO1—urinary bladder cancer	0.000126	0.000327	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	0.000125	0.000326	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	0.000125	0.000326	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	0.000118	0.000306	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	0.000105	0.000272	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—TYMP—urinary bladder cancer	0.0001	0.00026	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—TYMS—urinary bladder cancer	9.74e-05	0.000253	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	9.63e-05	0.00025	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	9.63e-05	0.00025	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PPARG—urinary bladder cancer	9.54e-05	0.000248	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—GPX1—urinary bladder cancer	9.22e-05	0.00024	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	9.17e-05	0.000238	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—NAT2—urinary bladder cancer	9.06e-05	0.000236	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	9.05e-05	0.000235	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	8.51e-05	0.000221	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—RRM2—urinary bladder cancer	7.82e-05	0.000203	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	7.51e-05	0.000195	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—ENO2—urinary bladder cancer	7.24e-05	0.000188	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	7.24e-05	0.000188	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	7.03e-05	0.000183	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PPARG—urinary bladder cancer	6.9e-05	0.000179	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	6.63e-05	0.000172	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PTEN—urinary bladder cancer	6.55e-05	0.00017	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—EP300—urinary bladder cancer	6.24e-05	0.000162	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.84e-05	0.000152	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	5.43e-05	0.000141	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.87e-05	0.000127	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PTEN—urinary bladder cancer	4.73e-05	0.000123	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.53e-05	0.000118	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—EP300—urinary bladder cancer	4.51e-05	0.000117	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.48e-05	0.000116	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.48e-05	0.000116	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.29e-05	0.000111	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.21e-05	0.000109	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.96e-05	0.000103	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.21e-05	8.34e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.08e-05	8.01e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.52e-05	6.56e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.2e-05	5.72e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.1e-05	5.46e-05	CbGpPWpGaD
